Literature DB >> 2649017

The captopril test: an aid to investigation of hypertension.

C E Daman Willems1, V Shah, M Uchiyama, M J Dillon.   

Abstract

Twenty three children aged from 5 to 16 with mild to moderate hypertension were investigated using the orally active angiotensin converting enzyme inhibitor captopril. Falls in both systolic and diastolic blood pressure after a single dose of captopril were significantly correlated with initial plasma renin activity. In addition, some information about the aetiology of hypertension was deduced from the renin response to captopril. The blood pressure response to captopril is a useful screening test for renin dependent hypertension in childhood.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2649017      PMCID： PMC1791859          DOI： 10.1136/adc.64.2.229

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  10 in total

1.  A slowly developing pressor response to small concentrations of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension.

Authors:  C J DICKINSON; J R LAWRENCE
Journal:  Lancet       Date:  1963-06-22       Impact factor: 79.321

2.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

Review 3.  Blood pressure and hypertension in childhood and adolescence.

Authors:  E P Leumann
Journal:  Ergeb Inn Med Kinderheilkd       Date:  1979

4.  Reactive hyper-reninaemia to angiotensin blockade identifies renovascular hypertension.

Authors:  D B Case; S A Atlas; J H Laragh
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

5.  Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.

Authors:  D H Streeten; G H Anderson; J M Freiberg; T G Dalakos
Journal:  N Engl J Med       Date:  1975-03-27       Impact factor: 91.245

6.  Plasma renin activity and aldosterone concentration in children.

Authors:  M J Dillon; J M Ryness
Journal:  Br Med J       Date:  1975-11-08

7.  Measurement of plasma renin activity by semi-micro radioimmunoassay of generated angiotensin I.

Authors:  M J Dillon
Journal:  J Clin Pathol       Date:  1975-08       Impact factor: 3.411

8.  The captopril test for identifying renovascular disease in hypertensive patients.

Authors:  F B Muller; J E Sealey; D B Case; S A Atlas; T G Pickering; M S Pecker; J J Preibisz; J H Laragh
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

9.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

10.  Factors related to first dose hypotensive effect of captopril: prediction and treatment.

Authors:  G P Hodsman; C G Isles; G D Murray; T P Usherwood; D J Webb; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-12
  10 in total
  4 in total

1.  Inadequacy of captopril challenge test for diagnosing renovascular hypertension in children and adolescents.

Authors:  B Gauthier; H Trachtman; R Frank; G Pillari
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

2.  Hypertension in paediatrics: can pre- and post-captopril technetium-99m dimercaptosuccinic acid renal scans exclude renovascular disease?

Authors:  I Minty; M F Lythgoe; I Gordon
Journal:  Eur J Nucl Med       Date:  1993-08

3.  Captopril test in children with reflux nephropathy.

Authors:  R M Hamed; G Ellis; M Levy; G A McLorie; J W Balfe
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

Review 4.  Evaluation and management of bilateral renal artery stenosis in children: a case series and review.

Authors:  D Ellis; R Shapiro; V P Scantlebury; R Simmons; R Towbin
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.